Any feedback?
Literature summary for 3.4.14.5 extracted from
- Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes (2008), Expert. Opin. Emerg. Drugs, 13, 593-607.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | DPP-4 inhibition is an oral therapy for type 2 diabetes | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| alogliptin | competitive and reversible inhibitor | Homo sapiens |  |
| NVP DPP728 | - |
Homo sapiens | |
| saxagliptin | BMS-477118, competitive and reversible inhibitor | Homo sapiens | |
| sitagliptin | MK-0431 or Januvia, competitive and reversible inhibitor | Homo sapiens | |
| vildagliptin | LAF237 or Galvus, competitive and reversible inhibitor | Homo sapiens | |
Natural Substrates/ Products (Substrates)
| Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| glucagon-like peptide 1 + H2O | Homo sapiens | - |
? | - |
? | |
| glucose-dependent insulinotropic polypeptide + H2O | Homo sapiens | - |
? | - |
? | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| glucagon-like peptide 1 + H2O | - |
Homo sapiens | ? | - |
? | |
| glucose-dependent insulinotropic polypeptide + H2O | - |
Homo sapiens | ? | - |
? | |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| dipeptidyl peptidase-4 | - |
Homo sapiens |
| DPP-4 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
